Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Midwife, a dream job

After her son was born, Lea Zerbe decided to become a midwife and enrolled in a training program at Helios Mariahilf Hospital in Hamburg.
Read the story
In battle against the coronavirus

Fresenius is taking comprehensive measures to ensure healthcare is available for patients during the COVID-19 pandemic.
Read the story
My 50 years of dialysis

I am Susanne Williams from Adelaide. I am 66 years old – and this is my story of 50 years of dialysis.
Read the story
Growing up with parenteral nutrition

How two brave adventurers from Switzerland are exploring the world step-by-step.
Read the story

News

Brief News
Fresenius Medical Care gets FDA approval for Biofine® PD solution bags

Fresenius Medical Care North America announced today that the U.S. Food and Drug Administration (FDA) has approved DELFLEX® peritoneal dialysis solutions in Biofine®, an innovative bag material. The milestone marks another important step in the company’s commitment to grow home dialysis through new and improved products. Biofine material generates less waste and is PVC-free, to the benefit of the environment. The new Biofine peritoneal dialysis solutions bag has a user-friendly design for easy storage and use, and will be produced on a new manufacturing line in the company’s Knoxville, Tennessee plant. It is expected to be made available first to a limited number of U.S. patients this fall.

October 20, 2020Fresenius Medical Care

Fresenius announces changes to Supervisory Board

October 13, 2020Fresenius
Brief News
Fresenius Helios expands reporting on quality standards

As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.

October 09, 2020Fresenius Helios

Brief News
Fresenius Kabi launches its first RFID smart-labeled product in the U.S.

Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

October 08, 2020Fresenius Kabi
Fresenius Medical Care presents new strategy and announces new medium-term targets through 2025 at Capital Markets Day

Fresenius Medical Care is excellently positioned for continued, sustainable growth. At today’s virtual-only Capital Markets Day, management presented the company’s new growth strategy and a new medium-term outlook for the coming five years to analysts and investors.
October 08, 2020Fresenius Medical Care
Brief News
Fresenius Medical Care partners with Applied Health Signals company Livongo in the U.S.

Fresenius Medical Care North America announced a partnership with Livongo, the leading Applied Health Signals company in the U.S. This will enable the company to better deliver targeted, real-time care coordination services to patients with late-stage chronic kidney disease (CKD) under value based care agreements with insurance providers and the federal government, as well as manage their comorbidities such as diabetes and hypertension. By deploying innovative technologies and services, the partnership allows patients to receive personalized interventions including remote monitoring, biometrics, education, nutrition, weight management, and emotional support, with the goal to improve outcomes, slow progression of CKD, and reduce the overall cost of care. With earlier intervention, the company also seeks to increase optimal dialysis starts, as well as offer earlier evaluation of transplantation and home dialysis options.

October 08, 2020Fresenius Medical Care

Brief News
Fresenius Helios enters healthcare agreement with hotel operator in Spain

Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health care to guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.

October 07, 2020Fresenius Helios
Brief News
Fresenius Medical Care expands collaboration with U.S. insurer Humana

Fresenius Medical Care North America and the health insurer Humana are broadening their collaboration. The goal is improved, better coordinated and more holistic care for eligible members, for example through expanded access to CKD care coordination services and transitional care units. In addition, the existing clinical network contract, which provides eligible members with access to dialysis at more than 2,600 Fresenius Kidney Care clinics, is being implemented as a value-based payment model. This means that reimbursement will be based on meeting agreed quality improvement and patient outcome goals.

October 06, 2020Fresenius Medical Care

The Power of Ideas and the people behind them: Fresenius Medical Care publishes 2020 Global Annual Medical Report

September 24, 2020Fresenius Medical Care
Fresenius successfully places bonds with a volume of one billion euros

September 21, 2020Fresenius

Brief News
2021 DRG inflator for German hospitals set at 2.53%

The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 14, 2020Fresenius Helios
Fresenius Medical Care to issue bonds with a volume of 1 billion US-dollars

September 10, 2020Fresenius Medical Care

Annual General Meeting: Stable business model proves its strength; 27th consecutive dividend increase approved

August 28, 2020Fresenius
Fresenius Medical Care: Strong growth despite the pandemic, Annual General Meeting approves 23rd straight dividend increase

August 27, 2020Fresenius Medical Care

Brief News
Fresenius Helios publishes study on intensive care COVID-19 patients

Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.

August 25, 2020Fresenius Helios
Fresenius acquires Malteser hospitals in German state of North Rhine-Westphalia

August 20, 2020Fresenius Helios

Brief News
Fresenius Kabi introduces RFID Smart Labels for Medications in the U.S.

Beginning in Q4 2020, Fresenius Kabi will introduce smartlabels with radio frequency identification (RFID) technology for medications frequently used in the operating room in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. The first products in the smartlabel portfolio are anesthesia and analgesia products in prefilled syringes and vials.

August 18, 2020Fresenius Kabi
Fresenius with solid H1 results – Accelerated earnings growth expected in H2 – New FY/20 guidance including COVID-19 effects

July 30, 2020Fresenius

Fresenius Medical Care delivers very strong second quarter results

July 30, 2020Fresenius Medical Care
Brief News
Curalie cooperates with ‘Wir für Gesundheit‘ and Debeka

The Berlin-based digital health company Curalie, a subsidiary of the Fresenius healthcare group, has entered a cooperation agreement with the “Wir für Gesundheit” quality medical care network and the health insurer Debeka. In the first step, a prevention app through which regular medical check-ups can be carried out, along with other functions, will be added to PlusCard. A supplementary company health insurance that companies can offer to their employees, PlusCard was jointly developed by “Wir für Gesundheit” and Debeka and has been offered since 2014. Additional digital components are planned for the prevention app, including a telemedicine function for the care of chronically ill patients.

July 29, 2020Fresenius

Fresenius Medical Care in Schweinfurt joins environmental pact of Germany’s Bavaria state

July 14, 2020Fresenius Medical Care
Brief News
Fresenius Helios publishes sustainability report

Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals, the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

July 08, 2020Fresenius Helios

Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged

July 08, 2020Fresenius
Fresenius Medical Care holds virtual General Meeting on August 27, 2020 – dividend proposal unchanged

July 08, 2020Fresenius Medical Care

Dr. Sebastian Biedenkopf to succeed Dr. Jürgen Götz on Management Board of Fresenius

June 23, 2020Fresenius
Brief News
Fresenius Medical Care expands TCU network in the USA

Fresenius Medical Care North America intends to open more than 100 new transitional care units (TCUs) this year. These units will help people recently diagnosed with kidney failure learn about the treatment options available to them including home dialysis, and become more empowered in managing their own care. TCUs are designed to be a separate space within a dialysis center with staff dedicated to onboarding patients new to dialysis during their first weeks of treatment, assisting patients transitioning between modalities, and supporting individuals returning to dialysis from transplant. Fresenius Medical Care North America has been rapidly opening TCUs, with a total of 65 operating already, in support of its home growth strategy. The company has found that over 50 percent of TCU patients will choose a home dialysis modality.

June 19, 2020Fresenius Medical Care

Brief News
Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

June 15, 2020Fresenius Kabi
Fresenius Medical Care expands production at St. Wendel plant in response to higher demand caused by COVID-19 pandemic

June 15, 2020Fresenius Medical Care

Fresenius Helios acquires hospital in western Germany

May 29, 2020Fresenius Helios
Brief News
Fresenius Kabi enters marketing agreement for biosimilar product

Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

May 28, 2020Fresenius Kabi

Disclaimer All news

NEXT EVENT

October 29, 2020 - 01:30 PM | Bad Homburg, Germany

Conference Call Q3 2020, Fresenius

Live Webcast

Webcast Import (ICS)

NEXT EVENT

Library

All Downloads

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us